Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
200
¥100 millionWording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedOperating profitNot disclosed → ¥200 100 million
ROENot disclosed → At least 8%
Only the target level is shown because the current level for comparison was not provided.Statements about the use of capital
Payout ratio / DOE policyTargeting a consolidated total payout ratio of at least 40% and, in principle, implementing progressive dividends. The applicable period is the medium-term plan period.The payout ratio is the proportion of profit paid out as dividends, while DOE is the ratio of dividends to net assets.
Treasury share acquisition policyThe company will conduct flexible share repurchases during the medium-term plan period.
Key initiatives
01Growth Strategy
02Active investment in the healthcare business
03Development and creation of high-value-added product lines
04Development and cultivation of new businesses
05Structural Reform
06Major manufacturing transformation
07Strengthening the Management Platform
08Digital utilization strategy
09Human Resources Strategy
10R&D strategy
Plan assumptionsAgainst a backdrop of geopolitical risks and other factors, uncertainties including supply chain disruptions and fluctuations in raw material prices are expected to persist.
Risks identified by the company
Geopolitical risk
Supply chain disruptions
Fluctuations in Raw Material Prices
Reason for revision or withdrawal
Against a backdrop of geopolitical risks and other factors, uncertainties including supply chain disruptions and fluctuations in raw material prices are expected to persist. Based on this premise, the company needs to ensure sustained growth and improve its earnings capacity.
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan 2030 |
| Plan period | Starting fiscal year Not disclosed / Final year FY2030 / Wording in the document Five-year period ending in fiscal 2030 |
| Progress against the plan | Formulated |
| Operating profit target | Not disclosed → ¥200 100 million |
| ROE target | Not disclosed → At least 8% |
| Payout ratio / DOE policy | Targeting a consolidated total payout ratio of at least 40% and, in principle, implementing progressive dividends. The applicable period is the medium-term plan period. |
| Treasury share acquisition policy | The company will conduct flexible share repurchases during the medium-term plan period. |
| Plan assumptions | Against a backdrop of geopolitical risks and other factors, uncertainties including supply chain disruptions and fluctuations in raw material prices are expected to persist. |
| Key initiatives | Growth Strategy, Active investment in the healthcare business, Development and creation of high-value-added product lines, Development and cultivation of new businesses, Structural Reform, Major manufacturing transformation, Strengthening the Management Platform, Digital utilization strategy, Human Resources Strategy, R&D strategy |
| Reason for revision or withdrawal | Against a backdrop of geopolitical risks and other factors, uncertainties including supply chain disruptions and fluctuations in raw material prices are expected to persist. Based on this premise, the company needs to ensure sustained growth and improve its earnings capacity. |
| Risks identified | Geopolitical risk, Supply chain disruptions, Fluctuations in Raw Material Prices |
| Date of board resolution | 13 May 2026 |
| Publication date | 13 May 2026 |
Items this document does not state (12)
Sales TargetOperating profit margin targetNet income targetROIC targetCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsResults under the previous planSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Uncertainties, including supply chain disruptions and fluctuations in raw material prices, are expected to persist against a backdrop of geopolitical risks and other factors. Based on this premise, the company needs to ensure sustained growth and improve its earnings capacity.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.